TRENTAL

This brand name is authorized in Austria, Croatia, Ecuador, Estonia, Germany, Hong Kong SAR China, Lithuania, Mexico, Netherlands, New Zealand, Singapore, Turkey, UK.

Active ingredients

The drug TRENTAL contains one active pharmaceutical ingredient (API):

1	Pentoxifylline UNII SD6QCT3TSU - PENTOXIFYLLINE
	Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation.
	Read more about Pentoxifylline

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRENTAL 400 Modified release tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C04AD03	Pentoxifylline	C Cardiovascular system → C04 Peripheral vasodilators → C04A Peripheral vasodilators → C04AD Purine derivatives
Discover more medicines within C04AD03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00281068, 01394455, 02857207, 03046184, 03046209, 03528842, 07515144
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	25.312-08-03, 28784-03-09, 5304-MEE-0720
EE	Ravimiamet	1009404
GB	Medicines & Healthcare Products Regulatory Agency	14856, 162793, 175969, 399370
HK	Department of Health Drug Office	05569
HR	Agencija za lijekove i medicinske proizvode	HR-H-361535572
LT	Valstybinė vaistų kontrolės tarnyba	1001904, 1075842, 1078898, 1091295
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	145M86, 82769
NL	Z-Index G-Standaard, PRK	24414
NZ	Medicines and Medical Devices Safety Authority	10876
SG	Health Sciences Authority	11723P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699809037724